P.CataneR.SheridanM
To qualify for Semaglutide GLP-1 weight loss treatment, a BMI of 30 or higher (indicating obesity) or a BMI of 27 or higher with weight-related health conditions is typically required
Summary Keywords autism spectrum disorder, prenatal drug exposure, valproic acid, selective serotonin reuptake inhibitor, maternal immune activation, hypertensive disorders of pregnancy, advanced parental age Citation Sato A, Kotajima-Murakami H, Tanaka M, Katoh Y and Ikeda K (2022) Influence of Prenatal Drug Exposure, Maternal Inflammation, and Parental Aging on the Development of Autism Spectrum Disorder
Available as both an injectable and oral medication, semaglutide mimics the GLP-1 hormone, reducing appetite for sustained weight loss
doi: 10.3390/pharmaceutics12020185 434 Varela-MoreiraAShiYFensMHAMLammersTHenninkWESchiffelersRM